Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
02/2012
02/21/2012US8119101 Anti-CD74 immunoconjugates and methods of use
02/21/2012CA2675025C Inhibitor of herpesvirus infection, method for inhibition of herpesvirus infection, and use thereof
02/21/2012CA2656124C Use of bacterial polysaccharides for biofilm inhibition
02/21/2012CA2568995C Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof
02/21/2012CA2534585C Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors
02/21/2012CA2434421C Manufacturing method of combined vaccine
02/21/2012CA2418962C Anti-dual integrin antibodies, compositions, methods and uses
02/21/2012CA2412460C Human monoclonal antibody against hepatitis c virus e2 glycoprotein
02/21/2012CA2409983C Viral variants and methods of using same
02/21/2012CA2407680C Dendritic cell co-stimulator molecules
02/21/2012CA2389080C Mistletoe lectins as mucosal adjuvants
02/21/2012CA2373300C Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
02/21/2012CA2354045C New cancer treatments
02/21/2012CA2322055C Novel mechanically sensitive mammal potassium channel family activated by polyunsaturated fatty acids and their use particularly for screening medicines
02/21/2012CA2302866C Genetically modified tumor-targeted bacteria with reduced virulence
02/21/2012CA2269085C Rainbow trout il1.beta.; encoding nucleic acid; materials and methods
02/21/2012CA2264592C Bioconjugates and delivery of bioactive agents
02/21/2012CA2263835C Stimulus-inducible i (kappa)b kinase [ikk] signalsome
02/21/2012CA2172180C A multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
02/21/2012CA2158936C Compositions and methods for utilizing conditionally lethal genes
02/16/2012WO2012021841A2 Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
02/16/2012WO2012021840A2 Materials and methods for designing autologous idiotype vaccines and treatment of b-cell malignancies
02/16/2012WO2012021834A1 Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
02/16/2012WO2012021786A2 Anti-hemagglutinin antibody compositions and methods of use thereof
02/16/2012WO2012021773A1 Antibodies to il-1beta and il-18, for treatment of disease
02/16/2012WO2012021730A2 Respiratory syncytial virus (rsv) vaccine
02/16/2012WO2012021558A1 Methods and compositions for preventing a condition
02/16/2012WO2012021512A2 Erythrocyte-binding therapeutics
02/16/2012WO2012021475A2 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
02/16/2012WO2012021469A1 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
02/16/2012WO2012021287A2 Methods for the treatment and prevention of metabolic disorders
02/16/2012WO2012021249A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
02/16/2012WO2012021247A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
02/16/2012WO2012021229A1 Staphylococcus aureus surface protein sa1789 and protective vaccine based thereon
02/16/2012WO2012021165A2 Methods and compositions for treating disorders associated with hyperactive immune system
02/16/2012WO2012020842A1 Complex having tumor vaccine effect, and use thereof
02/16/2012WO2012020622A1 Fragment of humanized anti-egfr antibody substituted-lysine variable fragment and use thereof
02/16/2012WO2012020367A1 Specific antibodies to g protein-coupled receptors and method for producing the same
02/16/2012WO2012020326A1 Adjuvanted vaccines for serogroup b meningococcus
02/16/2012WO2012020162A1 Use of antibodies against nk1, nk2 and/or nk3 receptors in cancer treatment
02/16/2012WO2012020124A1 Vaccine engineering
02/16/2012WO2012020072A1 Anti-syndecan-4 antibodies
02/16/2012WO2012020038A1 Anti-tenascin-c a2 antibodies and methods of use
02/16/2012WO2012019437A1 Bladder cancer tumor marker, antibiotic and application thereof
02/16/2012WO2012019354A1 Method for reducing dna impurities in viral compositions
02/16/2012WO2012019268A2 An immunogenic composition for use in a vaccine and an immunodiagnostic test kit for visceral leishmaniasis
02/16/2012WO2012007632A9 Use of edg2 inhibitors for treating rheumatoid arthritis
02/16/2012WO2011156619A3 Vaccine and methods to reduce campylobacter infection
02/16/2012WO2011126833A3 Anti-inflammatory factors
02/16/2012WO2011116014A9 Humanized antibodies to labyrinthin and uses thereof
02/16/2012WO2011112906A3 Novel immunogens and methods for discovery and screening thereof
02/16/2012WO2011109104A3 Molecular clone of hiv-1
02/16/2012US20120042400 Rtd receptor
02/16/2012US20120042399 Immunogenic peptides
02/16/2012US20120040010 Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
02/16/2012US20120039995 Arsenic compounds, their preparation methods and uses thereof
02/16/2012US20120039994 Vaccine composition containing synthetic adjuvant
02/16/2012US20120039993 Detection of Gene Expression
02/16/2012US20120039989 Erythrocyte-binding therapeutics
02/16/2012US20120039986 Compositions and methods for sirna inhibition of angiopoietin 1 and 2 and their receptor tie2
02/16/2012US20120039985 Dendritic cell modulation in post-ischemic wounds
02/16/2012US20120039984 Glycopeptide and uses thereof
02/16/2012US20120039980 Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
02/16/2012US20120039958 Compositions and methods for treatment of taupathy
02/16/2012US20120039956 Dry storage stabilizing composition for biological materials
02/16/2012US20120039943 Factors
02/16/2012US20120039942 Outer membrane vesicles and uses thereof
02/16/2012US20120039941 Engineered botulinum neurotoxin
02/16/2012US20120039940 Methods for treating uterine disorders
02/16/2012US20120039939 Compositions and methods for vaccine and virus production
02/16/2012US20120039938 Composition comprising the polyprotein ns3/ns4 and the polypeptide ns5b of hcv, expression vectors including the corresponding nucleic sequences and their therapeutic use
02/16/2012US20120039937 Induction of an immune response against dengue virus using the prime-boost approach
02/16/2012US20120039936 Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)
02/16/2012US20120039935 Methods of treating measles infectious disease in mammals
02/16/2012US20120039934 Adjuvant-sparing multi-dose influenza vaccination regimen
02/16/2012US20120039933 Methods for one-dose intradermal delivery for non-live trivalent influenza vaccine
02/16/2012US20120039932 Lentiviral Vectors Pseudotyped with a Sindbis Virus Envelope Glycoprotein
02/16/2012US20120039931 Dna composition encoding an immunogenic vegf receptor peptide and methods of use thereof
02/16/2012US20120039926 Compositions and Methods for Modulating Immunogenic Responses by Activating Dendritic Cells
02/16/2012US20120039925 Tuberculosis tb vaccine to prevent reactivation
02/16/2012US20120039924 Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
02/16/2012US20120039923 Modified HIV-1 Envelope Proteins
02/16/2012US20120039921 Poultry viral materials and methods related thereto
02/16/2012US20120039920 Hydrophobic monomers, hydrophobically-derivatized supports, and methods of making and using the same
02/16/2012US20120039919 Diabetes diagnostic, prophylactic, and therapeutic compositions and methods
02/16/2012US20120039917 Immunomodulating activities
02/16/2012US20120039916 Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells
02/16/2012US20120039915 Glioblastoma multiforme-reactive antibodies and methods of use thereof
02/16/2012US20120039914 Methods and compositions for using mhc class ii invariant chain polypeptides as a receptor for macrophage migration inhibitory factor
02/16/2012US20120039913 Selective Histamine H4 Receptor Antagonists for the Treatment of Vestibular Disorders
02/16/2012US20120039912 Rspondin-3 inhibition in bone disorders
02/16/2012US20120039911 Cd93 or use of soluble fragment thereof
02/16/2012US20120039910 Novel Use of IL-1beta Compounds
02/16/2012US20120039909 Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
02/16/2012US20120039908 Control of Protein Glycosylation and Compositions and Methods Relating Thereto
02/16/2012US20120039907 Polypeptides including modified constant regions
02/16/2012US20120039906 PD-1 Antibodies and PD-L1 Antibodies and Uses Thereof
02/16/2012US20120039905 The Role of p110 delta Signaling in Morbidity and Lung Pathology Induced by Influenza Virus Infection
02/16/2012US20120039904 Anti system asc amino acid transporter 2 (asct2) antibody
02/16/2012US20120039903 Methods for suppressing an immune response or treating a proliferative disorder
1 ... 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 ... 1823